GlassScriptPhysician profile
Meghan Elshoff
NPI 1306412044
$963.91
in general payments reported to CMS, 2019-2025
25 companies · $964 in 2025
The $964 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.92 |
| Education | $157.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $205.17 | 2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $75.73 | 2025 | |
| Novartis Pharmaceuticals Corporation | $72.65 | 2025 | |
| Celgene Corporation | $61.42 | 2025 | Reblozyl, Opdualag |
| Emd Serono, INC. | $48.52 | 2025 | |
| Adaptive Biotechnologies Corporation | $45.78 | 2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $41.88 | 2025 | |
| Eisai INC. | $41.86 | 2025 | |
| Tersera Therapeutics LLC | $37.67 | 2025 | Xermelo, Zoladex |
| Stemline Therapeutics INC. | $33.68 | 2025 | Elzonris, Orserdu |
| Astrazeneca Pharmaceuticals LP | $29.03 | 2025 | Imfinzi |
| Aveo Pharmaceuticals, INC. | $25.74 | 2025 | |
| Iovance Biotherapeutics, INC. | $22.39 | 2025 | Amtagvi |
| Abbvie INC. | $21.80 | 2025 | |
| Azurity Pharmaceuticals, INC. | $20.59 | 2025 | Vivimusta, Danziten |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $20.24 | 2025 | Orgovyx |
| Gilead Sciences, INC. | $19.77 | 2025 | Trodelvy |
| Incyte Corporation | $19.73 | 2025 | Jakafi |
| Merck Sharp & Dohme LLC | $19.64 | 2025 | Keytruda |
| Daiichi Sankyo INC. | $19.25 | 2025 | Injectafer |
| Beone Medicines USA, INC. | $19.00 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $17.41 | 2025 | |
| Genzyme Corporation | $16.69 | 2025 | |
| Syndax Pharmaceuticals, INC. | $14.24 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.03 | 2025 | Vpriv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Elshoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.